Small Pharma Inc. (DMT.V)
| Previous Close | 0.1500 |
| Open | 0.1500 |
| Bid | 0.1500 x N/A |
| Ask | 0.1650 x N/A |
| Day's Range | 0.1500 - 0.1550 |
| 52 Week Range | 0.0850 - 0.7000 |
| Volume | |
| Avg. Volume | 126,840 |
| Market Cap | 49.987M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0710 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Small Pharma Completes Enrollment in Phase IIa DMT-Assisted Psychotherapy Clinical Trial in Patients With Major Depressive Disorder
Dosing for primary endpoint now completeLONDON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has completed enrollment in the Phase IIa clinical trial of its intravenous (“IV”) formulation of N, N-dimethyltryptamine (“DMT”) candidate, SPL026, with psychotherapy for the treatment of Major Depressiv
- GlobeNewswire
Small Pharma Enters Into Automatic Share Purchase Plan
LONDON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announced that it has entered into an automatic share purchase plan (the “ASPP”) with Eight Capital (the “Broker”) in order to facilitate repurchases of the Company's common shares (the “Shares”) under its previously announced normal course issuer bid (the “NCIB
- GlobeNewswire
Small Pharma to Participate in Upcoming September Investor Conferences
LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, announces that George Tziras, Chief Executive Officer and Dr. Carol Routledge, Chief Medical and Scientific Officer, will participate in upcoming investor conferences this September. Details of the sessions are as follows: H.C. Wainwright 24th Annual Global Investment
